Breaking News

Sound Pharmaceuticals Receives $3.1M NIH Grant for COVID Treatment

To support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sound Pharmaceuticals, Inc. (SPI) has received a Cooperative Grant award from the National Center for Advancing Translational Sciences (NCATS) at the NIH for $3.1 milion to support the testing of SPI-1005 in two Phase 2 clinical trials for the treatment of COVID-19.   SPI-1005 is an oral capsule containing ebselen, a small molecule with novel anti-inflammatory properties being developed for several neurotologic, neuropsychiatric, and respiratory indications. Ebselen was recently shown to inhib...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters